Amarin Corporation plc reported financial results for the second quarter and first half of 2026. Total net revenue declined to $42.2 million from $72.7 million in Q2 2025, primarily due to a $25 million upfront payment received in the prior year period associated with its exclusive license agreement with Recordati S.p.A. for European commercialization. Operating expenses decreased by 59% to $27.0 million as the company completed its $70 million annual cost savings initiative. The company reported a net loss of $7.7 million, compared to $14.1 million in Q2 2025, and maintained a cash position of $314.6 million while remaining debt-free. In-market demand for VASCEPA/VAZKEPA grew 59% year-over-year across its global partner network, with European demand rising 69%. Amarin operates in the pharmaceutical industry, developing and commercializing cardiovascular treatments.